A laboratory-made molecule that increases dopamine-producing brain cells, quiets brain inflammation, and improves maze learning in rats and cell cultures. No person has been dosed in any published study, and nearly all findings come from one financially interested group. Ultraviolet light makes it damage genetic material; blocked dopamine breakdown conflicts with common medicines and foods. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated blood pressure | 110-120 / 70-80 mmHg | Detects the pressor response that monoamine oxidase inhibition can produce |
| Resting heart rate | 50-70 beats per minute | Tracks sympathetic drive alongside pressure |
| ALT | 10-26 U/L (men), 9-22 U/L (women) | Flags liver strain from a compound with no toxicology record |
| eGFR | Above 90 mL/min/1.73 m² | Confirms clearance capacity before repeated exposure |
| hs-CRP | Below 0.5 mg/L | Sets the inflammation baseline against which any anti-inflammatory claim is judged |
| Serum prolactin | No established target; change from own baseline, typical adult values 4-15 ng/mL | Falls when dopamine signaling rises, giving an indirect readout of dopaminergic effect |
| Complete blood count | Within standard laboratory reference limits | Detects unexpected marrow or immune effects during exposure that no study has characterized |
Cadence: Baseline before any exposure, repeated at two weeks, at six weeks, then every three to six months if exposure continues, with blood pressure recorded at home twice weekly throughout.